Day 1 – November 27th, 2009

Session 1
Antiangiogenesis & Tumor Biology
Chairman: Carlos Vallejos Sologuren

Antiangiogenesis & Rational use of Avastin
Román Pérez Soler - USA

Biomarkers in Oncology
Andrés Cardona - Colombia

Antiangiogenesis Biomarkers
Román Pérez Soler - USA

Session 2
Antiangiogenic therapy in mBC
Chairman: Fernando Salas Sanchez

Safety, Tolerability & Standard dose of Avastin in mBC
Henry Gómez - Peru

Taxanes and Avastin
Andrés Redondo - Spain

Correlation between Avastin mBC’s Phase III Studies
Enrique Díaz Cantón - Argentina

Session 3
RCC & Ovarian Cancer: current treatment approaches
Chairman: Rocío Reátegui Vásquez

Avastin Phase III mRCC trials: CALGB & AVOREN OS update
Juan José Zarba - Argentina

New concepts in mRCC treatment: sequencing treatment
Daniel Castellanos - Spain

Antiangiogenic therapy in metastatic Ovarian Cancer
Andrés Redondo - Spain

Session 4
Target therapies in GBM
Chairman: Juan Fernando Suazo Casanova

Update in GBM: Diagnosis and treatment
León Darío Ortiz - Colombia

Antiangiogenesis in GBM therapy
Andrés Cardona - Colombia

Day 2 – November 28th, 2009

Session 5
Anti VEGF prolonging survival in 1st and 2nd line mCRC
Chairman: Fernando Hurtado de Mendoza Acurio

PFS & OS: main efficacy endpoints in mCRC
Mario Barugel - Argentina

Avastin: survival irrespective of K-ras status
Enrique Grande - Spain

Session 6
New concepts in NSCLC therapy with Avastin
Chairman: Luis Mas López

VEGF Target in 1st line NSCLC
Luis Mas - Peru

ATLAS: improving survival in NSCLC
Román Pérez Soler - USA

Final Session
Closing Remarks & Panel of Experts
Chairman: Román Perez Soler

Avastin: confirmed efficacy in 1st line mBC
Enrique Díaz Cantón - Argentina

Avastin in mRCC: sequencing therapy improving OS
Daniel Castellanos - Spain

Avastin in GBM: a new alternative of treatment
Andrés Cardona - Colombia

Avastin: 1st line and beyond progression in mCRC
Enrique Grande - Spain

Avastin until progression for better outcomes in NSCLC
Román Pérez Soler - USA